ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 114 filers reported holding ACCELERON PHARMA INC in Q4 2014. The put-call ratio across all filers is 0.52 and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,950,000 | +5.4% | 69,503 | -7.3% | 1.52% | -20.7% |
| Q3 2017 | $2,799,000 | +11.0% | 74,990 | -9.6% | 1.92% | +39.5% |
| Q2 2017 | $2,522,000 | +2.5% | 82,990 | -10.8% | 1.38% | +11.1% |
| Q1 2017 | $2,461,000 | +3.7% | 92,990 | 0.0% | 1.24% | -20.4% |
| Q4 2016 | $2,373,000 | +96.6% | 92,990 | +178.9% | 1.56% | +156.9% |
| Q3 2016 | $1,207,000 | +5.8% | 33,340 | 0.0% | 0.61% | +9.8% |
| Q2 2016 | $1,141,000 | +15.6% | 33,340 | -10.9% | 0.55% | +17.4% |
| Q1 2016 | $987,000 | -51.7% | 37,404 | -10.7% | 0.47% | -47.8% |
| Q4 2015 | $2,043,000 | +93.3% | 41,892 | -1.3% | 0.90% | +72.7% |
| Q3 2015 | $1,057,000 | -21.4% | 42,463 | 0.0% | 0.52% | +2.6% |
| Q2 2015 | $1,344,000 | +55.9% | 42,463 | +87.5% | 0.51% | +29.3% |
| Q1 2015 | $862,000 | -48.0% | 22,647 | -46.8% | 0.39% | -37.6% |
| Q4 2014 | $1,658,000 | +390.5% | 42,549 | +334.0% | 0.63% | +363.2% |
| Q1 2014 | $338,000 | – | 9,805 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Artal Group S.A. | 1,400,000 | $133,378,000 | 3.73% |
| Foresite Capital Management III, LLC | 42,030 | $4,004,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 257,249 | $24,508,000 | 2.23% |
| Cormorant Asset Management, LP | 600,000 | $57,162,000 | 2.18% |
| Avoro Capital Advisors LLC | 1,040,000 | $99,081,000 | 1.96% |
| QVT Financial LP | 101,396 | $9,660,000 | 1.64% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,100,000 | $200,067,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 155,000 | $14,767,000 | 1.60% |
| Parkman Healthcare Partners LLC | 57,500 | $5,478,000 | 1.54% |
| Ikarian Capital, LLC | 187,700 | $17,882,000 | 1.42% |